Entropy Neurodynamics has reported 75% of patients achieved clinically meaningful symptom improvement in treatment-resistant ...

Ardelyx (NASDAQ:ARDX) executives said the company entered 2026 with “another significant year of growth” underway, ...

Thank you. At Ardelyx, we are building an innovative pipeline of medicines for patients with unmet medical needs. As we build on this momentum, our focus is on executing on our four key priorities: ...

IBS Intelligence (IBSi) is the world’s only pure-play Financial Technology focused research, advisory, and fintech news ...

IBS Intelligence (IBSi) is the world’s only pure-play Financial Technology focused research, advisory, and fintech news ...

Surveyed HCPs identified reduction of days on TPN as a top priority –– Improved quality of life, lower risk of infection and thrombosis viewed as key benefits of reduced TPN dependence –– Additional ...

(Chief Financial Officer Sue Hohenleitner) reported: “Our quarter-over-quarter total product revenues were $93.4 million compared to $67.8 million in the same period last year, representing 38% growth ...

Full-Year 2026 Guidance (Excluding Bausch + Lomb) -- Revenue expected at $5.25 billion–$5.4 billion (midpoint: 3% growth), ...

Good afternoon, and welcome to Bausch Health's First Quarter 2026 Earnings Conference Call. My name is Garen Sarafian, Vice President of Investor Relations. Participating in today's call are Thomas ...

Q1 2026 total product revenue of $93.4 million, reflecting 38% growth year-over-yearIBSRELA Q1 2026 revenue growth of 58% year-over-year to $70.1 ...

Caitlin Jones, 20, has retrograde cricopharyngeal dysfunction — also known as no burp syndrome. She noticed when she tried to ...

A woman from Yorkshire has said her rare condition has left her unable to burp for the last six years.